Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 28.29M 19.93M 17.45M 16.03M 14.95M 1.9B 28.83M 193M 74.66M 933M 74.92M 73.28M 3.22B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 28.06M 19.77M 17.31M 15.9M 14.83M 1.89B 28.59M 191M 74.05M 926M 74.31M 72.69M 3.19B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.03%
Yield 2024 *
-
Yield 2025 -
1 day+4.00%
1 week+23.81%
Current month+4.00%
1 month+52.94%
3 months+4.00%
6 months-23.53%
Current year-23.53%
1 week 0.11
Extreme 0.11
0.14
1 month 0.08
Extreme 0.075
0.14
Current year 0.07
Extreme 0.07
0.19
1 year 0.07
Extreme 0.07
0.34
3 years 0.04
Extreme 0.035
0.36
5 years 0.04
Extreme 0.035
0.36
10 years 0.04
Extreme 0.035
0.36
Manager TitleAgeSince
Chief Executive Officer - 30/06/2019
Director of Finance/CFO - 16/08/2022
Chief Tech/Sci/R&D Officer - 16/09/2024
Director TitleAgeSince
Director/Board Member - 05/12/2017
Director/Board Member - 30/06/2019
Chairman - 29/04/2025
Date Insider Type Main position Quantity % Market Cap.
06-04Sell

Director

200,000 0.1114%
06-04Sell

Chief Financial Officer

100,000 0.0557%
06-04Sell

Director

500,000 0.2786%
Change 5-day change 1-year change 3-year change Capi.($)
+4.00%+23.81%-60.61%+85.71% 19.92M
+1.86%+8.65%+56.45%+158.84% 1,063B
+3.57%+9.15%+68.70%+58.92% 611B
+3.99%+11.15%+37.41%+93.77% 444B
-1.20%-0.96%+26.12%+20.22% 324B
+4.94%+4.51%+39.76%+28.93% 285B
+2.42%+2.96%+30.77%+42.24% 283B
+2.47%+6.56%-24.26%-39.60% 219B
+3.55%+6.47%+28.79%+68.52% 195B
+4.21%+4.88%+17.49%+70.33% 156B
Average +1.56%+4.45%+22.06%+58.79% 358.07B
Weighted average by Cap. +0.68%+4.16%+41.94%+80.68%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.79 0.01 0.08 0.03 0.39 0.03 0.03 1.33
Net income -1.71M -1.2M -1.05M -968K -902K -115M -1.74M -11.64M -4.51M -56.31M -4.52M -4.42M -194M -3.53M -2.49M -2.18M -2M -1.87M -238M -3.6M -24.08M -9.32M -117M -9.35M -9.15M -401M
Net Debt -113K -79.35K -69.48K -63.83K -59.51K -7.57M -115K -768K -297K -3.71M -298K -292K -12.8M -231K -162K -142K -131K -122K -15.5M -235K -1.57M -608K -7.6M -611K -597K -26.2M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
02/07/26 CA$0.1300 +4.00% 51,102
30/06/26 CA$0.1250 0.00% 20,000
29/06/26 CA$0.1250 -10.71% 266,156
26/06/26 CA$0.1400 +27.27% 1,043,000
25/06/26 CA$0.1100 +4.76% 23,500

Annual profits - Rate of surprise